Latest
Follow-Up Results of Low-Dose Dasatinib for Chronic-Phase Chronic Myeloid Leukemia
Subgroup Analysis of Carfilzomib for Relapsed or Refractory Multiple Myeloma in Asian Patients
Survival Disparities in Pediatric Patients With Lymphoma Based on Ethnicity
CAR-T Therapy May Be More Effective When Administered Earlier in the Multiple Myeloma Treatment Continuum
Study Compares Anticoagulants for Antiphospholipid Syndrome
Analysis Determines Cost Effectiveness of Various Treatment Strategies for Multiple Myeloma
An Algorithm for Predicting Resistance to Hypomethylating Agents Using Genomic Biomarkers
Single Nucleotide Polymorphisms Associated With ALL in Children With Down Syndrome
Physician Experience With Rituximab Affected Rate of Early Discontinuation in NHL
Benefit of CD19-Targeted CAR-T Therapy in Patients With Transformed Waldenström Macroglobulinemia
Risk for Pulmonary Embolism Elevated for up to 18 Weeks After Surgery
Red Blood Cell Distribution Width May Be Prognostic for Survival in Light-Chain Amyloidosis
Featured Content
As Survival Increases in Beta Thalassemia, Renal Complications Emerge
Renal complications occur in more than half of patients with beta thalassemia, but research on their epidemiology and treatment is limited.
Advances in the Diagnosis of Type 1 von Willebrand Disease: Genetic Testing
Despite the increasing availability of gene sequencing, several barriers prevent it from having utility as a tool for diagnosis of type 1 von Willebrand disease.
Measurable Residual Disease: The Future of Multiple Myeloma Assessment?
Advances in technology for detecting measurable residual disease (MRD) are also raising questions regarding the role of MRD in managing multiple myeloma.
Implant-Associated Cancers: A Look Beyond BIA-ALCL
Recent and upcoming case reports suggest possible cases of gluteal and other implant-associated ALCLs, raising questions about the cancer risk across all types of implants.
Improving the Clinical Diagnosis and Classification of Gray Zone Lymphomas
Although gray zone lymphoma has distinct morphologic features, immunophenotyping can make classifying gray zone lymphoma challenging.
